HF 1020
Alternative Names: Enterotoxin B; EtxBLatest Information Update: 25 May 2016
At a glance
- Originator University of Bristol
- Developer Trident Pharmaceuticals
- Class Antiallergics; Antiasthmatics; Antihyperglycaemics; Antirheumatics; Bacterial proteins; Recombinant proteins; Skin disorder therapies
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 10 Sep 2010 Preclinical trials in Inflammation in United Kingdom (unspecified route)
- 11 Jul 2007 HF 1020 is available for licensing worldwide (http://www.hunter-fleming.com)
- 11 Jan 2002 Preclinical development for Allergic asthma in United Kingdom (Unknown route)